Validation of dried blood sampling for infliximab in IBD-patients <br>
Completed
- Conditions
- Inflammatory Bowel Disease10017969
- Registration Number
- NL-OMON43041
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
- Age from 18 years, either male or female
- Diagnosis of IBD
- Receiving infliximab therapy
Exclusion Criteria
- Contra-indication to infliximab (TBC, severe infections or congestive heart failure)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary: to investigate feasibility of DBS from finger prick for measuring<br /><br>infliximab drug levels and ATIs compared with the results of venepuncture serum<br /><br>sample measurements.</p><br>
- Secondary Outcome Measures
Name Time Method <p>To compare levels of albumin and CRP from DBS with the results of venepuncture<br /><br>serum sample measurement and to investigate feasibility of DBS from finger<br /><br>prick at home.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does dried blood sampling for infliximab affect TNF-alpha inhibition measurement in IBD patients compared to traditional methods?
What are the comparative advantages of dried blood spots over serum/plasma for monitoring infliximab efficacy in Crohn's disease and ulcerative colitis?
Which biomarkers in IBD correlate with infliximab concentration and therapeutic response using dried blood sampling techniques?
What adverse events are associated with dried blood sampling for infliximab in IBD, and how are they managed in clinical practice?
Can dried blood sampling for infliximab be adapted for other IBD biologics like adalimumab or ustekinumab in patient monitoring?